Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program

Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program

Abstract Background The Italian Renal Cell Cancer Early Access Program was an expanded access program that allowed access to nivolumab, for patients (pts) with metastatic renal cell carcinoma (mRCC) prior to regulatory approval. Methods Pts with previously treated advanced or mRCC were eligible to r...

Full description

Bibliographic Details
Main Authors: Elena Verzoni, Giacomo Cartenì, Enrico Cortesi, Diana Giannarelli, Andrea De Giglio, Roberto Sabbatini, Sebastiano Buti, Sabrina Rossetti, Francesco Cognetti, Francesca Rastelli, Alberto Sobrero, Daniele Turci, Cora N. Sternberg, Camillo Porta, Federico Cappuzzo, Giampaolo Tortora, Davide Tassinari, Stefano Panni, Antonio Pazzola, Gianmarco Surico, Alessandra Raimondi, Ugo De Giorgi, Giuseppe Procopio, on behalf of the Italian Nivolumab Renal Cell Cancer Early Access Program group
Format: Article
Language:English
Published: BMJ Publishing Group 2019-04-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Immunotherapy
Adverse events
Renal cell carcinoma
Expanded access trials
Online Access:http://link.springer.com/article/10.1186/s40425-019-0579-z

Internet

http://link.springer.com/article/10.1186/s40425-019-0579-z

Similar Items